Vireo Finally Guides — Into a Stock That Already Rode 1,462% and Gave Back a Third
A $1B revenue run-rate, the first formal quarterly outlook in company history, a Minnesota grow that ran out of flower, and a New York story that quietly vanished
VREOF · Earnings Call · 2026-11-10
The quiet revolution: Vireo started guiding
The most consequential sentence on Vireo's third-quarter call wasn't a number. It was an admission of what the company had previously refused to do.
given the high number of acquisitions over the year and the timing uncertainty that it introduces, we have not been in a position previously to provide guidance. We do, however, feel it is important to share with investors how we are looking at the business.
What followed was the first real financial framework in the company's history: Q4 2026 revenue of $250–265 million with $45–48 million of adjusted EBITDA; Q1 2027 of $280–300 million and $53–56 million. Pending deals, if they had closed at the start of each quarter, would have added another $45–55 million of revenue and $5–6 million of EBITDA in Q4, and $50–60 million and $7–8 million in Q1. Management then set the policy going forward — sequential quarterly targets only, no full-year number, because the pending acquisitions pipeline moves faster than annual forecasting allows.
That formal guidance concept is new this quarter in the keyword record and absent from every prior quarter's set, which is exactly the tell. For a company whose Q3 GAAP revenue of $253.7 million was up 177% year-over-year, the absence of guidance had become the story; now a management that spent four calls deflecting the question has handed the market a yardstick to beat it with.
Total revenue of $209 million in the last filed quarter, up 335% year-over-year and 97% sequentially, with operating income of $14 million, represented the shape of a platform compounding through acquisition rather than organic pull. Q3 simply extended it.
Minnesota: the same promise, three calls running
The quarter's ugliness was state-specific. Minnesota retail fell roughly 10% sequentially in a market management itself described as growing. The explanation was unusually candid:
There is no flower in the market. And our grow actually had a couple of issues as we're opening our second facility, and we ran out of product. So when you run out of product in Minnesota, you have declining revenues.
That is the third consecutive call on which Minnesota was framed as a supply problem that was about to be solved. In August 2025 the CEO told analysts “there's going to be a shortage of supply in Minnesota. And all of the supply initially will come from either us or GTI” — John Michael Mazarakis, Chief Executive Officer · 2025-08-13 — a shortage he positioned as an opportunity. By May 2026 the tone was dismissive: “So I wouldn't worry about Minnesota. I think our Minnesota plan is to be the market leader by virtue of being the largest producer in the state.” — John Mazarakis, CEO · 2026-05-12 Now, in November, the largest producer ran out of product while commissioning a second facility. Investors should treat "the issue is resolved already" with the appropriate discount.
The organic picture is softer than the headline too. Pro forma retail same-store growth was 4% — down from the 7% figure that dominated prior calls, and only barely above the 3.7% inflation the CEO cited. He graded it “B+” — John Mazarakis, Chief Executive Officer · 2026-11-10, having told analysts in August that “7% in perpetuity is not, it's just not realistic” — John Mazarakis, CEO · 2026-08-11. Vireo is now a roll-up where the acquired math does the heavy lifting and the legacy stores roughly track inflation.
What Vireo stopped talking about: New York
For roughly two years, New York was a top-ranked theme — assets held for sale, a New York assets divestiture, litigation, a complicated social-equity partnership. In this quarter's keyword set, all of it disappears. Not de-emphasized — gone.
The reason is instructive. Rather than exiting New York, Vireo is now borrowing against it: a $60 million real estate term loan at a fixed 8.5%, secured by cultivation and production facilities in New York and Florida, announced after quarter-end. The strategy shift is consistent with the asset light framing management now applies to competitive markets, but it inverts the prior narrative, in which New York was an asset to be sold and a wholesale indoor-flower ambition was to be pursued. The new CapEx discipline is real — “I have a big sign in my office, just a reminder for me, that says we don't build cultivation” — John Mazarakis, Chief Executive Officer · 2026-11-10 — but owning a dozen facilities outright is a different kind of capital intensity than selling them.
Buybacks, leverage, and the shape of the balance sheet
Asked to rank capital allocation, the CEO did not hedge: “Buyback is by far my first choice. If I could buy back more stock, I would do it.” — John Mazarakis, Chief Executive Officer · 2026-11-10 The company repurchased 216,200 subordinate voting shares for about $2.5 million in the quarter. He also made the valuation argument explicitly: “we would never buy something even for 4x their EBITDA if we're trading 3x our EBITDA.” — John Mazarakis, Chief Executive Officer · 2026-11-10
The tension is the cash conversion behind that. Against $253.7 million of Q3 revenue and $42.7 million of adjusted EBITDA, the last filed quarter showed capital expenditure of $108 million on $209 million of revenue, and free cash flow less stock compensation of negative $113 million in that same quarter. The CEO's claim that “the industry is becoming a cash-generating industry now” — John Mazarakis, Chief Executive Officer · 2026-11-10 is directionally true at the EBITDA line; at the free-cash-flow line it is not yet true at Vireo. Management targets sub-1x EBITDA leverage and reported net debt of $186.2 million against $293 million of long-term debt and $106.8 million of cash — a credible number only if the guidance is hit.
The tape already voted — twice
This is where the dossier gets uncomfortable. Vireo's shares returned roughly 1,460% over the last 90 trading days, including a four-day stretch of roughly 2,240%. The stock peaked at $10.07 on July 8 and now sits about 34% below that high. On a $255 million market cap and a claimed annualized revenue run-rate above $1 billion, the re-rating was violent and has already begun to fade. Guidance is landing into a stock that has been re-priced once and is being re-priced again.
The regulatory backdrop peers are trading against — cannabis to Schedule III at NLCP, rescheduling of state licensed medical marijuana at TRUL, and the broader adult use market build-out — remains the industry's biggest free option, and Vireo's answer is unchanged from prior quarters: it isn't one. “I think that's sort of like a crystal ball question and agreeing to be in this space means that you are agreeing to deal with the adversity that comes with uncertainty.” — John Mazarakis, Chief Executive Officer · 2026-11-10The verdict: guidance is the genuine change here, and it matters — a consolidator that finally tells you what it earns is a different company from one that asks for faith. But the first number it gave came with a Minnesota grow that ran dry, a 4% same-store engine that is barely beating inflation, a New York asset it stopped trying to sell, and a share price that has already run and rolled over. The next two quarters decide whether Vireo is a disciplined acquirer with a cash machine attached, or a very fast roll-up with a capex bill.